<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="editorial"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Clin Diabetes Healthc</journal-id><journal-id journal-id-type="iso-abbrev">Front Clin Diabetes Healthc</journal-id><journal-id journal-id-type="publisher-id">Front. Clin. Diabetes Healthc.</journal-id><journal-title-group><journal-title>Frontiers in Clinical Diabetes and Healthcare</journal-title></journal-title-group><issn pub-type="epub">2673-6616</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38125705</article-id><article-id pub-id-type="pmc">PMC10731350</article-id><article-id pub-id-type="doi">10.3389/fcdhc.2023.1338656</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Diabetes and Healthcare</subject><subj-group><subject>Editorial</subject></subj-group></subj-group></article-categories><title-group><article-title>Editorial: Current understanding of complications associated with diabetes</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Srivastava</surname><given-names>Swayam Prakash</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/781975"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<institution>Hartman Institute of Therapeutic Organ Regeneration, Division of Regenerative Medicine, Department of Medicine, Weill Cornell Medicine</institution>, <addr-line>New York, NY</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited and Reviewed by: Wael Almahmeed, Cleveland Clinic Abu Dhabi, United Arab Emirates</p></fn><corresp id="fn001">*Correspondence: Swayam Prakash Srivastava, <email xlink:href="mailto:swayam.cdri@gmail.com">swayam.cdri@gmail.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>4</volume><elocation-id>1338656</elocation-id><history><date date-type="received"><day>15</day><month>11</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2023</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2023 Srivastava</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Srivastava</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><related-article related-article-type="commentary-article" id="RA1" xlink:href="https://www.frontiersin.org/research-topics/40427" ext-link-type="uri">Editorial on the Research Topic <article-title>Current understanding of complications associated with diabetes</article-title>
</related-article><kwd-group><kwd>diabetes</kwd><kwd>diabetic kidney disease</kwd><kwd>diabetic complication</kwd><kwd>diabetic endothelial dysfunction</kwd><kwd>SGLT-2 antagonists</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="25"/><page-count count="3"/><word-count count="1029"/></counts><custom-meta-group><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Diabetes Cardiovascular Complications</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Diabetes mellitus is a chronic metabolic disorder and is caused either by the inability of the pancreas to produce enough insulin or defects in the insulin action on the peripheral tissues, resulting in persistent hyperglycemia. Hyperglycemia is a key outcome of diabetes mellitus and chronic hyperglycemia leads to serious damage to many organs. In 2019, 48% of all mortalities caused by diabetes mellitus were observed in the subjects at or before the age of 70 years (<xref rid="B1" ref-type="bibr">1</xref>). The clinical data suggests that in 2015, 415 million people were supposed to develop diabetes mellitus and by 2040, this prevalence is estimated to grow to 642 million worldwide (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). By the year 2050, the number of diabetic patients in the United States will increase to 48.3 million (<xref rid="B4" ref-type="bibr">4</xref>) although 90% to 95% of the diabetes burden is due to type II diabetes (<xref rid="B4" ref-type="bibr">4</xref>). Diabetes-associated complications including cardiovascular dysfunctions, renal disorders, nerve-related diseases, hepatic disorders, blindness, and organ amputation are key reasons for increased mortality among diabetic patients. Moreover, diabetes-related complexities include microvascular, macrovascular, and nerved-related issues (<xref rid="B5" ref-type="bibr">5</xref>). Diabetic nephropathy, retinopathy, neuropathy, cardiovascular dysfunctions, and hypertension (<xref rid="B5" ref-type="bibr">5</xref>) are key microvascular and macrovascular complications. Diabetic nephropathy develops in approximately 40% of diabetic patients and is the main cause of chronic kidney disease worldwide (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B6" ref-type="bibr">6</xref>). As a result of diabetes mellitus, kidney fibrosis develops which is the leading cause of end-stage renal disease. Diabetes mellitus-related mesenchymal activations observed in the kidneys, heart, and vessels are the critical reason for extracellular matrix (ECM) synthesis, deposition, and fibrogenesis (<xref rid="B7" ref-type="bibr">7</xref>). Deposition of ECM, collagens, inflammatory cells, and irregulated action of cytokines and chemokine further results in organ fibrosis in diabetes (<xref rid="B8" ref-type="bibr">8</xref>). There are several drug molecules known for the treatment of diabetes mellitus and related complications; however, developing safe therapeutics is still a challenge. With the development of therapeutic options for diabetes and related complications, diabetic patients have a longer life. This article gives insights into the literature on the background of the complications associated with diabetes.</p><p>Reducing the levels of oxidative stress, enhancing mitochondrial quality, and regulating the inflammatory and mesenchymal activation in diabetic-related complications have demonstrated desirable results in preclinical settings (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). Such medications show a new therapeutic option for the treatment of diabetes and related complications; however, further research is desirable for better management.</p><p>Researchers have reported promising activity in flavone, chalcone, and isoflavone as inhibitors against, i.e., phosphotyrosine phosphatase 1B (PTP-1B), &#x003b1;-glucosidase, GLP-1, dipeptidyl peptidase-4 (DPP-4), aldose reductase, and sodium-glucose co-transporter-2 (SGLT-2) in type II diabetes (<xref rid="B11" ref-type="bibr">11</xref>). These effective molecules have promising antidiabetic activity in preclinical settings and mouse models of diabetes. Recently, tissue-specific angiopoietin-like protein 4 (ANGPTL4), macrophage-stimulating protein 1 (MST-1) inhibitors, and SGLT-2 inhibitors have been found to have tremendous activity in controlling diabetes and related complications. Recently, we have observed that enzyme catechol-o-methyl transferase (COMT) deficiency is involved in metabolic disorders and pre-eclampsia-associated phenotypes in mice (<xref rid="B12" ref-type="bibr">12</xref>). COMT by-product 2-methoxy estradiol (2-ME) treatment suppressed the phenotype of metabolic disorders and pre-eclampsia in the mouse models; however, a randomized clinical trial is needed in diabetic patients for the development of 2-ME into the usable form as a medicine (<xref rid="B12" ref-type="bibr">12</xref>).</p><p>Endothelial cell dysfunction is a critical feature of diabetes-related complications (<xref rid="B13" ref-type="bibr">13</xref>). Endothelial-to-mesenchymal transition (EndMT) is the process through which endothelial cells lose the endothelial characteristics and gain the features of mesenchymal cells (<xref rid="B14" ref-type="bibr">14</xref>). Conversion of endothelial cells into the EndMT phenotype is the crucial process to accelerate fibrosis-associated pathways resulting in the deposition of ECM and fibrogenesis-associated proteins (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Our research group identified three key endogenous molecules that are associated to cellular stability and regulation of mesenchymal cells and fibrogenesis, and these are 1) endothelial glucocorticoid receptors (GR), 2) endothelial fibroblast growth factor receptor 1 (FGFR1), and 3) endothelial sirtuin 3 (SIRT3). Deficiency of either GR, FGFR1, or SIRT3 protein levels causes significantly diminished levels of fatty acid oxidation and activation of the inflammatory cascade in the endothelial cells itself and also to tubules in diabetic conditions, resulting in severe fibrotic responses in the diabetic kidneys and heart (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>). Defective fatty acid metabolism is critical in renal fibrosis (<xref rid="B23" ref-type="bibr">23</xref>). GR regulates canonical Wnt signaling and IL-6 levels. FGFR1 signaling is important for restoring antifibrotic microRNAs such as miR-29s and miR-let-7s, whereas SIRT3 regulates metabolic flux by targeting pyruvate kinase M2 tetramer-to-dimer formation (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B24" ref-type="bibr">24</xref>). The cumulative effects lead to cellular leakage, defects in the permeability, EndMT activations, and related fibrosis in the kidneys and heart in the diabetic condition (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Podocyte GR plays a critical role in regulating fibrosis in the diabetic glomeruli. Podocyte GR mitigates the Wnt signaling and elevates the levels of fatty acid oxidation and, therefore, is associated with the reduction in the levels of EndMT in glomerular endothelial cells, suggesting that GR loss in podocytes disrupts the important crosstalk between podocytes and endothelial cells in diabetes (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>In this Research Topic, <ext-link xlink:href="https://doi.org/10.3389/fcdhc.2022.831128" ext-link-type="uri">Huang et&#x000a0;al.</ext-link> demonstrated the crucial role of angiotensin-converting enzyme (ACE) in diabetic nephropathy and retinopathies. The authors demonstrated that elevated levels of serum ACE are related to DN progression or retina impairment in diabetic patients. This study will facilitate the identification of biomarkers for the management of diabetes-related complications. In another study, the authors discussed how hand manifestations reflect a systemic profibrotic state and are key clinical biomarkers of current or future internal organ fibrosis (<ext-link xlink:href="https://doi.org/10.3389/fcdhc.2023.1198782" ext-link-type="uri">Phatak et&#x000a0;al.</ext-link>). A study by <ext-link xlink:href="https://doi.org/10.3389/fcdhc.2023.1167852" ext-link-type="uri">Sacareau et&#x000a0;al.</ext-link> demonstrated the screening of CKD patients among diabetic subjects in French Guiana. This study links diabetes and hypertension, the two most obvious risk factors for developing CKD, in human subjects.</p><sec sec-type="conclusion" id="s1"><title>Conclusion</title><p>This Research Topic highlights new cellular mechanisms in diabetes-related complications and identifies new molecules for the treatment of organ fibrosis, neuropathies, and foot ulcers. We speculate that this Research Topic will provide valuable information that could be used in the management of diabetes-related complications.</p></sec><sec sec-type="author-contributions" id="s2"><title>Author contributions</title><p>SS: Conceptualization, Investigation, Software, Supervision, Validation, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing.</p></sec></body><back><sec sec-type="COI-statement" id="s3"><title>Conflict of interest</title><p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="disclaimer" id="s4"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wesolowska-Andersen</surname><given-names>A</given-names></name><name><surname>Brorsson</surname><given-names>CA</given-names></name><name><surname>Bizzotto</surname><given-names>R</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Tura</surname><given-names>A</given-names></name><name><surname>Koivula</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study</article-title>. <source>Cell Rep. Med.</source> (<year>2022</year>) <volume>3</volume>:<fpage>100477</fpage>.<pub-id pub-id-type="pmid">35106505</pub-id>
</mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alicic</surname><given-names>RZ</given-names></name><name><surname>Rooney</surname><given-names>MT</given-names></name><name><surname>Tuttle</surname><given-names>KR</given-names></name></person-group>. <article-title>Diabetic kidney disease: challenges, progress, and possibilities</article-title>. <source>Clin. J. Am. Soc. Nephrol.</source> (<year>2017</year>) <volume>12</volume>:<page-range>2032&#x02013;45</page-range>.</mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Saeedi</surname><given-names>P</given-names></name><name><surname>Karuranga</surname><given-names>S</given-names></name><name><surname>Pinkepank</surname><given-names>M</given-names></name><name><surname>Ogurtsova</surname><given-names>K</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><etal/></person-group>. <article-title>IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title>. <source>Diabetes Res. Clin. Pract.</source> (<year>2022</year>) <volume>183</volume>:<fpage>109119</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.diabres.2021.109119</pub-id>
<pub-id pub-id-type="pmid">34879977</pub-id>
</mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>AD</given-names></name><name><surname>Harris-Hayes</surname><given-names>M</given-names></name><name><surname>Schootman</surname><given-names>M</given-names></name></person-group>. <article-title>Epidemiology of diabetes and diabetes-related complications</article-title>. <source>Phys. Ther.</source> (<year>2008</year>) <volume>88</volume>:<page-range>1254&#x02013;64</page-range>.</mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Defronzo</surname><given-names>RA</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>RR</given-names></name><name><surname>Herman</surname><given-names>WH</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Type 2 diabetes mellitus</article-title>. <source>Nat. Rev. Dis. Primers</source> (<year>2015</year>) <volume>1</volume>:<fpage>15019</fpage>.<pub-id pub-id-type="pmid">27189025</pub-id>
</mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Warren</surname><given-names>AM</given-names></name></person-group>. <article-title>A promising outlook for diabetic kidney disease</article-title>. <source>Nat. Rev. Nephrol.</source> (<year>2019</year>) <volume>15</volume>:<fpage>68</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">30532022</pub-id>
</mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lovisa</surname><given-names>S</given-names></name><name><surname>Lebleu</surname><given-names>VS</given-names></name><name><surname>Tampe</surname><given-names>B</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Vadnagara</surname><given-names>K</given-names></name><name><surname>Carstens</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis</article-title>. <source>Nat. Med.</source> (<year>2015</year>) <volume>21</volume>:<fpage>998</fpage>&#x02013;<lpage>1009</lpage>.<pub-id pub-id-type="pmid">26236991</pub-id>
</mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name></person-group>. <article-title>Epigenetics and epigenomics in diabetic kidney disease and metabolic memory</article-title>. <source>Nat. Rev. Nephrol.</source> (<year>2019</year>) <volume>15</volume>:<page-range>327&#x02013;45</page-range>.</mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>PZ</given-names></name><name><surname>Szeto</surname><given-names>CC</given-names></name></person-group>. <article-title>Mitochondrial dysfunction in diabetic kidney disease</article-title>. <source>Clin. Chim. Acta</source> (<year>2019</year>) <volume>496</volume>:<page-range>108&#x02013;16</page-range>.</mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name></person-group>. <article-title>Loss of mitochondrial control impacts renal health</article-title>. <source>Front. Pharmacol.</source> (<year>2020</year>) <volume>11</volume>:<fpage>543973</fpage>.<pub-id pub-id-type="pmid">33362536</pub-id>
</mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fralick</surname><given-names>M</given-names></name><name><surname>Jenkins</surname><given-names>AJ</given-names></name><name><surname>Khunti</surname><given-names>K</given-names></name><name><surname>Mbanya</surname><given-names>JC</given-names></name><name><surname>Mohan</surname><given-names>V</given-names></name><name><surname>Schmidt</surname><given-names>MI</given-names></name></person-group>. <article-title>Global accessibility of therapeutics for diabetes mellitus</article-title>. <source>Nat. Rev. Endocrinol.</source> (<year>2022</year>) <volume>18</volume>:<fpage>199</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="pmid">35039662</pub-id>
</mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanasaki</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Kudoh</surname><given-names>S</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Deficiency in catechol-o-methyltransferase is linked to a disruption of glucose homeostasis in mice</article-title>. <source>Sci. Rep.</source> (<year>2017</year>) <volume>7</volume>:<fpage>7927</fpage>.<pub-id pub-id-type="pmid">28801594</pub-id>
</mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>JG</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group>. <article-title>Endothelial to mesenchymal transition represents a key link in the interaction between inflammation and endothelial dysfunction</article-title>. <source>Front. Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>294</fpage>.<pub-id pub-id-type="pmid">29515588</pub-id>
</mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name></person-group>. <article-title>MicroRNAs in kidney fibrosis and diabetic nephropathy: roles on EMT and endMT</article-title>. <source>BioMed. Res. Int.</source> (<year>2013</year>) <volume>2013</volume>:<fpage>125469</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2013/125469</pub-id>
<pub-id pub-id-type="pmid">24089659</pub-id>
</mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Hedayat</surname><given-names>AF</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name></person-group>. <article-title>microRNA crosstalk influences epithelial-to-mesenchymal, endothelial-to-mesenchymal, and macrophage-to-mesenchymal transitions in the kidney</article-title>. <source>Front. Pharmacol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>904</fpage>.<pub-id pub-id-type="pmid">31474862</pub-id>
</mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name><name><surname>Tripathi</surname><given-names>P</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name></person-group>. <article-title>Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease</article-title>. <source>Int. J. Mol. Sci.</source> (<year>2021</year>) <volume>22</volume>. doi: <pub-id pub-id-type="doi">10.3390/ijms22116027</pub-id>
</mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Setia</surname><given-names>O</given-names></name><name><surname>Dardik</surname><given-names>A</given-names></name><name><surname>Fernandez-Hernando</surname><given-names>C</given-names></name><name><surname>Goodwin</surname><given-names>J</given-names></name></person-group>. <article-title>Podocyte glucocorticoid receptors are essential for glomerular endothelial cell homeostasis in diabetes mellitus</article-title>. <source>J. Am. Heart Assoc.</source> (<year>2021</year>) <volume>10</volume>:<elocation-id>e019437</elocation-id>. doi: <pub-id pub-id-type="doi">10.1161/JAHA.120.019437</pub-id>
<pub-id pub-id-type="pmid">34308664</pub-id>
</mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Setia</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><name><surname>Koya</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy</article-title>. <source>Nat. Commun.</source> (<year>2021</year>) <volume>12</volume>, <fpage>2368</fpage>.<pub-id pub-id-type="pmid">33888696</pub-id>
</mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name></person-group>. <article-title>Loss of endothelial glucocorticoid receptor accelerates organ fibrosis in db/db mice</article-title>. <source>Am. J. Physiol. Renal Physiol.</source> (<year>2023</year>). doi: <pub-id pub-id-type="doi">10.1101/2023.03.20.533532</pub-id>
</mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Kanasaki</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Effect of antifibrotic microRNAs crosstalk on the action of N-acetyl-seryl-aspartyl-lysyl-proline in diabetes-related kidney fibrosis</article-title>. <source>Sci. Rep.</source> (<year>2016</year>) <volume>6</volume>:<fpage>29884</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep29884</pub-id>
<pub-id pub-id-type="pmid">27425816</pub-id>
</mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Nitta</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway</article-title>. <source>Cell Death Dis.</source> (<year>2017</year>) <volume>8</volume>:<elocation-id>e2965</elocation-id>. doi: <pub-id pub-id-type="doi">10.1038/cddis.2017.353</pub-id>
<pub-id pub-id-type="pmid">28771231</pub-id>
</mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Endothelial FGFR1 (Fibroblast growth factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of diabetic mice</article-title>. <source>Hypertension</source> (<year>2020</year>) <volume>76</volume>:<page-range>1935&#x02013;44</page-range>. doi: <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15587</pub-id>
</mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kang</surname><given-names>HM</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>P</given-names></name><name><surname>Ko</surname><given-names>YA</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Chinga</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development</article-title>. <source>Nat. Med.</source> (<year>2015</year>) <volume>21</volume>:<fpage>37</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25419705</pub-id>
</mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Takagaki</surname><given-names>Y</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name><name><surname>Kanasaki</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys</article-title>. <source>iScience</source> (<year>2021</year>) <volume>24</volume>:<fpage>102390</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.isci.2021.102390</pub-id>
<pub-id pub-id-type="pmid">33981977</pub-id>
</mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>SP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kitada</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Goodwin</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis</article-title>. <source>Cell Death Dis.</source> (<year>2018</year>) <volume>9</volume>:<fpage>997</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41419-018-1057-0</pub-id>
<pub-id pub-id-type="pmid">30250024</pub-id>
</mixed-citation></ref></ref-list></back></article>
